Loss of CEACAM1 in hepatocytes causes hepatic fibrosis
© 2024 The Authors. European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation..
BACKGROUND: The role of insulin resistance in hepatic fibrosis in Metabolic dysfunction-Associated SteatoHepatitis (MASH) remains unclear. Carcinoembryonic Antigen-related Cell Adhesion Molecule1 protein (CEACAM1) promotes insulin clearance to maintain insulin sensitivity and repress de novo lipogenesis, as bolstered by the development of insulin resistance and steatohepatitis in AlbuminCre + Cc1fl/fl mice with liver-specific mouse gene encoding CEACAM1 protein (Ceacam1) deletion. We herein investigated whether these mice also developed hepatic fibrosis and whether hepatic CEACAM1 is reduced in patients with MASH at different fibrosis stages.
METHODS: AlbuminCre + Cc1fl/fl mice were fed a regular or a high-fat diet before their insulin metabolism and action were assessed during IPGTT, and their livers excised for histochemical, immunohistochemical and Western blot analysis. Sirius red staining was used to assess fibrosis, and media transfer was employed to examine whether mutant hepatocytes activated hepatic stellate cells (HSCs). Hepatic CEACAM1 protein levels in patients with varying disease stages were assessed by ELISA.
RESULTS: Hepatocytic deletion of Ceacam1 caused hyperinsulinemia-driven insulin resistance emanating from reduced hepatic insulin clearance. AlbuminCre + Cc1fl/fl livers showed inflammation, fibrosis and hepatic injury, with more advanced bridging and chicken-wire hepatic fibrosis under high-fat conditions. Media transferred from hepatocytes isolated from mutant mice activated control HSCs, likely owing to their elevated endothelin1 content. Interestingly, hepatic CEACAM1 levels were lower in the livers of patients with MASH and declined gradually with advanced fibrosis stage.
CONCLUSIONS: Hepatic CEACAM1 levels declined with progression of MASH in humans. The phenotype of AlbuminCre + Cc1fl/fl mice assigned a key role to CEACAM1 loss from hepatocytes in hepatic fibrosis independently of other liver cells.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
European journal of clinical investigation - (2024) vom: 21. Feb., Seite e14177 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zaidi, Sobia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Fibrosis stage |
|---|
| Anmerkungen: |
Date Revised 25.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1111/eci.14177 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368715175 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368715175 | ||
| 003 | DE-627 | ||
| 005 | 20240229151718.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240222s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/eci.14177 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1305.xml |
| 035 | |a (DE-627)NLM368715175 | ||
| 035 | |a (NLM)38381498 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zaidi, Sobia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Loss of CEACAM1 in hepatocytes causes hepatic fibrosis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 25.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024 The Authors. European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation. | ||
| 520 | |a BACKGROUND: The role of insulin resistance in hepatic fibrosis in Metabolic dysfunction-Associated SteatoHepatitis (MASH) remains unclear. Carcinoembryonic Antigen-related Cell Adhesion Molecule1 protein (CEACAM1) promotes insulin clearance to maintain insulin sensitivity and repress de novo lipogenesis, as bolstered by the development of insulin resistance and steatohepatitis in AlbuminCre + Cc1fl/fl mice with liver-specific mouse gene encoding CEACAM1 protein (Ceacam1) deletion. We herein investigated whether these mice also developed hepatic fibrosis and whether hepatic CEACAM1 is reduced in patients with MASH at different fibrosis stages | ||
| 520 | |a METHODS: AlbuminCre + Cc1fl/fl mice were fed a regular or a high-fat diet before their insulin metabolism and action were assessed during IPGTT, and their livers excised for histochemical, immunohistochemical and Western blot analysis. Sirius red staining was used to assess fibrosis, and media transfer was employed to examine whether mutant hepatocytes activated hepatic stellate cells (HSCs). Hepatic CEACAM1 protein levels in patients with varying disease stages were assessed by ELISA | ||
| 520 | |a RESULTS: Hepatocytic deletion of Ceacam1 caused hyperinsulinemia-driven insulin resistance emanating from reduced hepatic insulin clearance. AlbuminCre + Cc1fl/fl livers showed inflammation, fibrosis and hepatic injury, with more advanced bridging and chicken-wire hepatic fibrosis under high-fat conditions. Media transferred from hepatocytes isolated from mutant mice activated control HSCs, likely owing to their elevated endothelin1 content. Interestingly, hepatic CEACAM1 levels were lower in the livers of patients with MASH and declined gradually with advanced fibrosis stage | ||
| 520 | |a CONCLUSIONS: Hepatic CEACAM1 levels declined with progression of MASH in humans. The phenotype of AlbuminCre + Cc1fl/fl mice assigned a key role to CEACAM1 loss from hepatocytes in hepatic fibrosis independently of other liver cells | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a fibrosis stage | |
| 650 | 4 | |a hepatic stellate cells | |
| 650 | 4 | |a insulin extraction | |
| 650 | 4 | |a insulin resistance | |
| 650 | 4 | |a steatohepatitis | |
| 700 | 1 | |a Asalla, Suman |e verfasserin |4 aut | |
| 700 | 1 | |a Muturi, Harrison T |e verfasserin |4 aut | |
| 700 | 1 | |a Russo, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Abdolahipour, Raziyeh |e verfasserin |4 aut | |
| 700 | 1 | |a Belew, Getachew Debas |e verfasserin |4 aut | |
| 700 | 1 | |a Iglesias, Maria Benitez |e verfasserin |4 aut | |
| 700 | 1 | |a Feraudo, Mary |e verfasserin |4 aut | |
| 700 | 1 | |a Leon, Lensay |e verfasserin |4 aut | |
| 700 | 1 | |a Kuo, Enoch |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Xiuli |e verfasserin |4 aut | |
| 700 | 1 | |a Kumarasamy, Sivarajan |e verfasserin |4 aut | |
| 700 | 1 | |a Ghadieh, Hilda E |e verfasserin |4 aut | |
| 700 | 1 | |a Gatto-Weis, Cara |e verfasserin |4 aut | |
| 700 | 1 | |a Zarrinpar, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Duarte, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Najjar, Sonia M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of clinical investigation |d 1970 |g (2024) vom: 21. Feb., Seite e14177 |w (DE-627)NLM000003107 |x 1365-2362 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:21 |g month:02 |g pages:e14177 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/eci.14177 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 21 |c 02 |h e14177 | ||